[{"id":"f3aa5ebc-ff8a-48a1-8ade-20d99888b813","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821933","created_at":"2023-04-20T14:03:56.574Z","updated_at":"2024-07-02T16:35:10.455Z","phase":"Phase 1/2","brief_title":"RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC","source_id_and_acronym":"NCT05821933","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Ivesa (firmonertinib) • RC108"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-10"},{"id":"cc3db3b8-b381-4e3e-8f3a-6478dfee9150","acronym":"","url":"https://clinicaltrials.gov/study/NCT04617314","created_at":"2021-01-19T20:33:47.665Z","updated_at":"2024-07-02T16:35:18.619Z","phase":"Phase 1","brief_title":"A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT04617314","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RC108"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/10/2021","start_date":" 03/10/2021","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-20"},{"id":"4b9588e8-34ef-4f39-9824-5762f04f1e2a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05628857","created_at":"2022-11-29T15:57:45.073Z","updated_at":"2024-07-02T16:35:27.481Z","phase":"Phase 2","brief_title":"A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor","source_id_and_acronym":"NCT05628857","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RC108"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 10/15/2024","primary_completion_date":" 10/15/2024","study_txt":" Completion: 10/15/2025","study_completion_date":" 10/15/2025","last_update_posted":"2023-11-30"}]